AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02885025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: broccoli sprout extract placebo
Description: a tablet similar to the actual broccoli sprout extract though without BSE.
Study NCT02885025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: broccoli sprout extract placebo
Description: a tablet similar to the actual broccoli sprout extract though without BSE.
Study NCT02885025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline nasal spray
Description: normal saline to replace nasal fluticasone in specific arms of the study
Study NCT02885025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline nasal spray
Description: normal saline to replace nasal fluticasone in specific arms of the study
Study NCT02118961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)
Description: 0.5 mL, subcutaneous injection
Study NCT02118961 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)
Description: 0.1 mL, subcutaneous injection
Study NCT01715740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine (CHM)
Description: Each CHM capsule, weighing 500mg, consists of XFS 250 mg and QSFFT 250 mg.
Study NCT01715740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated powder with similar taste, color, odor to intervention Chinese herbal medicine
Study NCT02869880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Pre-Consent Discussion
Description: The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision-parent, patient, healthcare provider and research staff.
Study NCT02869880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pre-consent Discussion
Description: Standard pre-consent discussion for a clinical trial
Study NCT01554241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D3 2000 IU/day
Description: 2000 IU/day D3
Study NCT01554241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D3 4000 IU/day
Description: vitamin D3 4000 IU/day
Study NCT01554241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D3 50,000 IU weekly
Description: vitamin D3 50,000 IU/week
Study NCT01554241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 800 IU/day
Description: vitamin D3 800 IU/day
Study NCT01524796 — intervention group
Intervention type: OTHER
Intervention: No intervention. Non-interventional study
Description: No intervention. Non-interventional study
Study NCT02248519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Gastrectomy
Description: Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
Study NCT02248519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Gastrectomy
Description: Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy. If laparoscopic resection does not seem feasible during surgery, the procedure may be converted to an open gastrectomy.
Study NCT02154698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 22-gauge Standard Needle
Description: Acquisition of lymph nodes samples using the 22-gauge Standard Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
Study NCT02154698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 22-gauge ProCore Needle
Description: Acquisition of lymph nodes samples using the 22-gauge ProCore Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
Study NCT00074048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL22
Description: Dosing via IV on Days 1,3, and 5.
Study NCT03605485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Pillows CPAP mask
Description: Investigative Nasal pillows Mask to be used for OSA therapy
Study NCT01897688 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islet Cell Transplant
Study NCT01106690 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.
Study NCT01106690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.
Study NCT01106690 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone.
Study NCT01106690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The patient's stable dose of metformin background therapy should be continued throughout the study.
Study NCT01106690 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: The patient's stable dose of metformin background therapy should be continued throughout the study.
Study NCT01106690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: The patient's stable dose of pioglitazone background therapy should be continued throughout the study.
Study NCT01106690 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pioglitazone
Description: The patient's stable dose of pioglitazone background therapy should be continued throughout the study.
Study NCT00099333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Exenatide 5 mcg subcutaneously injected twice daily for 4 weeks; then 10 mcg subcutaneously injected twice daily for 12 weeks.
Study NCT00099333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin will be taken according to the subject's current regimen
Study NCT00998296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: EGFR inhibitor
Study NCT00998296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: VEGF inhibitor
Study NCT01291732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: single dose of matching placebo
Study NCT01291732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 135585 XX
Description: single dose of low, medium or high dose of BI 135585 XX
Study NCT03968562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor
Description: 2% Doxycline Cream in Generic Aquaphor or Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration.
Study NCT03968562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor
Description: 2% Doxycline Cream in Generic Aquaphor or Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration.
Study NCT00965172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caphosol
Description: Oral rinse of calcium phosphate solution five times daily beginning on day one of chemotherapy.
Study NCT00965172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baking Soda
Description: Oral rinse of baking soda solution as per standard of care five times daily beginning on day one of chemotherapy.
Study NCT02052518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: These participants will receive the enhanced intervention including decision support and problem solving skills in addition to the standard of care for the individuals in the Nuturing Family Network Home Visition Program
Study NCT02052518 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Experimental
Description: These participants will receive the enhanced intervention including decision support and problem solving skills in addition to the standard of care for the individuals in the Nuturing Family Network Home Visition Program
Study NCT03478709 — intervention group
Intervention type: OTHER
Intervention: volume expansion
Description: Volume expansion when the patient has a dependent preload evaluated by a positive leg lever test (variation of more than 10% of the VES). It corresponds to the intravenous administration of 500 ml of Ringer lactate over 10 min.
Study NCT03478709 — intervention group
Intervention type: OTHER
Intervention: norepinephrine
Description: Vasopressor agent when the patient has persistent arterial hypotension related to postoperative vasoplegia syndrome. Norepinephrine is administered during persistent hypotension (MAP \<60mmHg) despite volume expansion. It corresponds to continuous intravenous norepinephrine administration to obtain a MAP of more than 70 mmHg
Study NCT03385980 — intervention group
Intervention type: OTHER
Intervention: Proteomic analysis
Description: Proteomic analysis of tissues collected from all sites of disease, guided by either imaging performed prior to the patient's death or post-mortem findings. Peripheral blood mononuclear cells (PBMC) will be collected with the purpose of identifying somatic changes occurring specifically in the tumor cells and not in normal DNA of the same patient.
Study NCT04341870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarilumab
Description: Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1
Study NCT04341870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1
Study NCT04341870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)
Study NCT04341870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine: oral administration, 600mg QD (200mg TID) from D1 to D10 (total duration 10 days)
Study NCT03529591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasty (SLT)
Description: In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
Study NCT03529591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasty
Description: In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
Study NCT03678519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function test
Description: Pulmonary Function tests using Spirometry. It will show following indices of ventilatory functions: Forced vital capacity (FVC), Forced expiratory volume in the 1st second (FEV1) and Forced expiratory volume in the 1st second as a percentage of the Forced vital capacity (FEV1/FVC %).
Study NCT02309242 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Neuropsychological assessment, MRI
Description: All subjects will be imaged (MRI) on the same 3T Philips scanner with a 32-channel phased-array head coil, located in the radiology department at UZ Leuven. For the neuropsychological assessment we will implement an extended neuropsychological assessment battery: ANT, CMS, Rey, BRIEF, WISC III, PedsQL, STAI, BDi, achenbach questionnaires
Study NCT02106390 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal group B Vaccine, rMenB+OMV NZ
Description: 4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
Study NCT02106390 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal group B Vaccine, rMenB+OMV NZ
Description: 4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
Study NCT02106390 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal ACWY Conjugate Vaccine, MenACWY
Description: 4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
Study NCT02106390 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine, MenACWY
Description: 4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
Study NCT03809104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality-based rehabilitation programs
Description: A virtual reality (VR)-based rehabilitation program that lasts for 12 weeks, twice per week, 30 minutes per time. The program was combined with progressive resistant training and functional movement of dominant upper (UE) limb. The device of the VR including one computer, one oculus headset, and one hand-hold sensor. The rehabilitation secession contains 4 different VR games in total, including (1) Leap Motion Blocks (2) Slum Ball VR Tournament (3) VR Super Sports 10th Edition- Basketball (4) VR Super Sports 10th Edition- Soccer.
Study NCT00790842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by mouth days 1-21 of a 28-day cycle. There is a 7 day rest (days 22-28). Continue until disease progression or unacceptable toxicity.
Study NCT00790842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg given by mouth days 1, 8, 15 and 22 of a 28-day cycle. Continue until disease progression or unacceptable toxicity.
Study NCT00790842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Description: Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.
Study NCT03869047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine +bupivacaine
Description: patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine, total volume 20 ml
Study NCT03869047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20% .
Study NCT01471288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carum Cravi
Description: 40mg/kg of body weight
Study NCT01471288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01052337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anaesthetics: sevofluorane
Description: 0.5%of sevofluorane with air
Study NCT04444453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Pedometer
Description: Pedometer worn on wrist
Study NCT04442802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty
Description: Under local anesthesia the percutaneous arterial access will be created. Digital subtraction angiography of the whole limb will be performed. Occlusive-stenotic lesion of the superficial femoral and / or popliteal artery will be crossed with a guidewire. The plain old (non drug-eluting) will be positioned in the affected arterial segment and inflated up to nominal pressure. After balloon deflation and extraction the completion angiography will be performed. Presence (yes/no) and severity (grades A-B or C-F according to NHLBI classification) of dissection will be assessed independently by 3 study investigators basing on DSA images in 2 directions. Decision to classify the dissection as severe (grade C-F) and to perform the bailout stenting will be done by the agreement between at least 2 from 3 investigators.
Study NCT04442802 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transluminal angioplasty
Description: Under local anesthesia the percutaneous arterial access will be created. Digital subtraction angiography of the whole limb will be performed. Occlusive-stenotic lesion of the superficial femoral and / or popliteal artery will be crossed with a guidewire. The plain old (non drug-eluting) will be positioned in the affected arterial segment and inflated up to nominal pressure. After balloon deflation and extraction the completion angiography will be performed. Presence (yes/no) and severity (grades A-B or C-F according to NHLBI classification) of dissection will be assessed independently by 3 study investigators basing on DSA images in 2 directions. Decision to classify the dissection as severe (grade C-F) and to perform the bailout stenting will be done by the agreement between at least 2 from 3 investigators.
Study NCT03682770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab will be administered subcutaneously (SC) in a single-use, pre-filled glass syringe every two weeks (Q2W)
Study NCT03682770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching dupilumab
Description: Placebo matching dupilumab is prepared in the same formulation without the addition of protein
Study NCT03682770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR101
Description: AR101 will be provided in dose-escalating capsules and then sachets during maintenance phase
Study NCT03328091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional pre-test genetic counseling
Description: Participant meets with a genetic counselor at the Center for Cancer Genetics and Prevention and traditional pre-test cancer genetic counseling is provided
Study NCT03328091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-test video education
Description: The video is designed to mirror the educational components of a traditional genetic counseling visit
Study NCT05240027 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Vape use survey
Description: pre \& post test surveys
Study NCT03802292 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: YQ23
Description: Single dose of YQ23 delivered via intravenous route. Ascending dose levels will be evaluated
Study NCT03802292 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Single dose of the matching placebo delivered via intravenous route.
Study NCT03760042 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Within-Subject Active vs Placebo Topical Applications
Description: Crisaborole 2% ointment (right side) and Placebo vehicle ointment (left side)
Study NCT03760042 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Within-Subject Active vs. Placebo Topical Applications
Description: Crisaborole 2% ointment (left side) and Placebo vehicle ointment (right side)
Study NCT01537705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuron012703 (Medical Food)
Description: 2 capsules twice daily for sixty days.
Study NCT02783807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyenez Retinal Camera v200
Study NCT02783807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volk Pictor Ret 1
Study NCT03262844 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Conservative treatment
Description: The conservative treatment group will be given diet and nursing guidance, then the drug treatment or physiotherapy will be given according to the conditions of patients. Patients with bladder dysfunction will be guided to perform routine intermittent catheterization with help of their parents.
Study NCT03262844 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsule surgery
Description: In the multiple segments of the spine, articular facet joint and intervertebral disc will be resected to achieve the effect of decompression.~Specific surgical segments, osteotomy range, decompression degree of each patient needs to be designed individually.
Study NCT03008057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: vitamin D supplement, 4000 IU tablet daily , one time a day, for 3 months
Study NCT03008057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D placebo
Description: vitamin D placebo tablet (Containing starch powder), one time a day, for 3 months
Study NCT00774566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PV-Isolation RF
Description: Radiofrequency
Study NCT00774566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PV-Isolation Cryo
Description: Cryo-Balloon